GlaxoSmithKline Invests in India

Published on: 

GlaxoSmithKline will build a new solid dosage manufacturing facility in India.

GlaxoSmithKline (GSK) announced that it would build a new pharmaceutical manufacturing facility in India. During a visit to India in mid-November, GSK CEO Sir Andrew Witty said the location of the new factory is yet to be finalized, but that the lead site is in Bangalore.

The new Rs. 864 crore ($138 million) factory is GSK’s latest commitment to its manufacturing network in India where the company has invested Rs. 1017 crore ($162 million) over the last decade. When complete, the new factory will make pharmaceutical products for the Indian market at a rate of up eight billion tablets and one billion capsules a year. The facility, expected to be operational by 2017, will also include a warehouse, site infrastructure, and utilities to support the manufacturing and packing of the medicines.

Around 8500 people work in India for GSK. The company has the following factories in India: three for consumer healthcare products (Nabha, Sonepat, and Rajahmundry), one for vaccines packaging, and one for pharmaceuticals products, both located in Nashik.


Source: GlaxoSmithKline